(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 February 2014 (27.02.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/032021 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C12N 5/071* (2010.01)
C12P 21/08 (2006.01) *C07K 19/00* (2006.01)

(21) International Application Number:
PCT/US2013/056504

(22) International Filing Date:
23 August 2013 (23.08.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/692,448 23 August 2012 (23.08.2012) US

(71) Applicants: **AGENSYS, INC.** [US/US]; 1800 Stewart Street, Santa Monica, CA 90404 (US). **SEATTLE GENETICS, INC.** [US/US]; 2182 30th Drive S.e., Bothell, WA 98021 (US).

(72) Inventors; and

(71) Applicants : **MORRISON, Robert, Kendall** [GB/US]; 1044 Yale Street, Santa Minica, CA 90403 (US). **AN, Zili** [US/US]; 2914 Arizona Avenue, Apt. #3, Santa Monica, CA 90404 (US). **MORRISON, Karen Jane, Meyrick** [GB/US]; 1044 Yale Street, Santa Monica, CA 90403 (US). **SNYDER, Josh** [US/US]; 953 21st Street, Apt. B, Santa Monica, CA 90403 (US). **JIA, Xiao-chi** [US/US]; 2262 Beverly Drive, Los Angeles, CA 90034 (US).

(74) Agents: **MULLEN, James J.** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

Figure 5. Efficacy of Ha15-10ac12vcMMAE in a Subcutaneously Established Xenograft Model of Human Bladder Cancer AG-B7 in SCID Mice



Note: Extraneous treatment arms in this experiment are not shown in this figure.

(57) Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

WO 2014/032021 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*